Media stories about T2 Biosystems (NASDAQ:TTOO) have been trending somewhat positive this week, Accern reports. The research group identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. T2 Biosystems earned a news impact score of 0.10 on Accern’s scale. Accern also assigned media coverage about the medical equipment provider an impact score of 47.0234137405991 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the headlines that may have effected Accern Sentiment’s analysis:
- T2 BIOSYSTEMS, INC. – StreetInsider.com (streetinsider.com)
- T2 Biosystems Inc (TTOO) Given Consensus Recommendation of “Hold” by Brokerages (americanbankingnews.com)
- As T2 Biosystems (TTOO) Market Valuation Declined, Lagoda Investment Management LP Lifted Holding by $4.85 … – Hill Country Times (hillcountrytimes.com)
- T2 Biosystems (TTOO) Offers Prlim. Q4 Results, Provides Update on T2Bacteria Panel (streetinsider.com)
- Zacks Investment Research Downgrades T2 Biosystems (TTOO) to Hold (americanbankingnews.com)
Shares of T2 Biosystems (TTOO) traded up $0.34 during trading on Monday, reaching $5.01. 535,800 shares of the company were exchanged, compared to its average volume of 452,250. T2 Biosystems has a one year low of $2.50 and a one year high of $6.99. The company has a quick ratio of 5.28, a current ratio of 5.40 and a debt-to-equity ratio of 2.25. The stock has a market capitalization of $179.48, a P/E ratio of -2.64 and a beta of 1.48.
A number of brokerages recently issued reports on TTOO. Zacks Investment Research downgraded shares of T2 Biosystems from a “buy” rating to a “hold” rating in a research note on Saturday. Canaccord Genuity reiterated a “buy” rating and issued a $6.00 price target on shares of T2 Biosystems in a research note on Monday, October 30th. HC Wainwright began coverage on shares of T2 Biosystems in a research note on Wednesday, October 18th. They issued a “buy” rating and a $8.00 price target for the company. Finally, ValuEngine upgraded shares of T2 Biosystems from a “strong sell” rating to a “sell” rating in a research note on Wednesday, September 13th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. T2 Biosystems presently has a consensus rating of “Hold” and an average price target of $6.54.
T2 Biosystems Company Profile
T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).
What are top analysts saying about T2 Biosystems? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for T2 Biosystems and related companies.